This page in English
Laddar profil information

Publikationer

A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor
He S, Johnsson H, Zabczyk M, Hultenby K, Cao H, Blombäck M
British journal of haematology 2013;160(6):806-16

In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban
He S, Wallèn H, Bark N, Blombäck M
Journal of thrombosis and thrombolysis 2013;35(2):131-9

Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease
Mobarrez F, He S, Broijersen A, Wiklund B, Antovic A, Antovic J, et al
THROMBOSIS AND HAEMOSTASIS 2011;106(2):344-52

Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke
Rooth E, Wallen Nh, Blomback M, He S
THROMBOSIS RESEARCH 2011;127(1):51-6

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*
Blomback M, He S, Bark N, Wallen Hn, Elg M
BRITISH JOURNAL OF HAEMATOLOGY 2011;152(6):758-65

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis
He S, Blomback M, Bark N, Johnsson H, Wallen Nh
THROMBOSIS AND HAEMOSTASIS 2010;103(5):1076-84

Effects of Acetylsalicylic Acid on Increase of Fibrin Network Porosity and the Consequent Upregulation of Fibrinolysis
He S, Bark N, Wang H, Svensson J, Blomback M
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2009;53(1):24-9

In Vitro Effects of Argatroban, Lepirudin, Bivalirudin, and Danaparoid on Fibrin Gel Permeability
He S, Wallen H, Johnsson H, Blomback M
SEMINARS IN THROMBOSIS AND HEMOSTASIS 2008;:91-96

A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma
He S, Zhu K, Skeppholm M, Vedin J, Svensson J, Egberg N, et al
THROMBOSIS AND HAEMOSTASIS 2007;98(4):871-82

Platelet activity, coagulation, and fibrinolysis during exercise in healthy males - Effects of thrombin inhibition by argatroban and enoxaparin
Li Nl, He S, Blomback M, Hjemdahl P
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2007;27(2):407-13

Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma
Antovic A, Blomback M, Sten-linder M, Petrini P, Holmstrom M, He S
BLOOD COAGULATION & FIBRINOLYSIS 2005;16(8):585-96

Marked increase of fibrin gel permeability with very low dose ASA treatment
Antovic A, Perneby C, Ekman Gj, Wallen Hn, Hjemdahl P, Blomback M, et al
THROMBOSIS RESEARCH 2005;116(6):509-17

Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials
He S, Cao H, Antovic A, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 2005;16(1):61-7

The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia
He S, Ekman Gj, Hedner U
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2005;3(2):272-9

Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation
Yoo G, Blomback M, Schenck-gustafsson K, He S
BRITISH JOURNAL OF HAEMATOLOGY 2003;121(1):123-9

Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance
Antovic A, Blomback M, Bremme K, Van Rooijen M, He S
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2003;1(12):2531-5

On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin
Edlund M, Blomback M, He S
BLOOD COAGULATION & FIBRINOLYSIS 2003;14(6):593-8

The role of recombinant factor VIIa(FVIIa) in fibrin structure in the absence of FVIII/FIX
He S, Blomback M, Ekman Gj, Hedner U
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2003;1(6):1215-9

Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII
Antovic Jp, Antovic A, He S, Tengborn L, Blomback M
HAEMOPHILIA 2002;8(6):781-6

The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism
Antovic A, Blomback M, Bremme K, He S
BLOOD COAGULATION & FIBRINOLYSIS 2002;13(3):181-6

Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein
He S, Cao Hl, Magnusson Cgm, Eriksson-berg M, Mehrkash M, Schenck-gustafsson K, et al
THROMBOSIS RESEARCH 2001;103(3):241-8

A simple and rapid laboratory method for determination of haemostasis potential in plasma II. Modifications for use in routine laboratories and research work
He S, Antovic A, Blomback M
THROMBOSIS RESEARCH 2001;103(5):355-61

Hypercoagulation in surgical postmenopausal women having hormone replacement with overdose estradiol
He S, Bremme K, Silveira A, Van Rooijen M, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 2001;12(8):677-81

Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system
He S, Blomback M, Yoo G, Sinha R, Henschen-edman Ah
FIBRINOGEN 2001;:531-5

Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy
He S, Wramsby M, Bokarewa M, Blomback M, Bremme K
JOURNAL OF THROMBOSIS AND THROMBOLYSIS 2000;9(3):277-81

A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results
He S, Bremme K, Blomback M
THROMBOSIS RESEARCH 1999;96(2):145-56

Haemostatic, endothelial and lipoprotein parameters and blood pressure levels in women with a history of preeclampsia
He S, Silveira A, Hamsten A, Blomback M, Bremme K
THROMBOSIS AND HAEMOSTASIS 1999;81(4):538-42

Fibrin D-dimer levels in preeclamptic pregnancies with birth of small-for-gestational-age neonates
He S, Bremme K, Blomback M
HYPERTENSION IN PREGNANCY 1998;17(2):217-226

Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia
He S, Bremme K, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1997;8(4):232-8

Decrease in plasminogen activator inhibitor type 2 related more to placental function and intrauterine fetal growth than to severity of preeclampsia
He S, Bremme K, Almqvist I, Blomback M
HYPERTENSION IN PREGNANCY 1996;15(2):171-182

Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia
He S, Bremme K, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1995;6(8):703-8

INCREASED CONCENTRATIONS OF LACTATE-DEHYDROGENASE IN PREGNANCY WITH PREECLAMPSIA - A PREDICTOR FOR THE BIRTH OF SMALL-FOR-GESTATIONAL-AGE INFANTS
He S, Bremme K, Kallner A, Blomback M
GYNECOLOGIC AND OBSTETRIC INVESTIGATION 1995;39(4):234-8

Visa alla publikationer